Drug class in one race
IL-23 p19 drugs for Psoriatic Arthritis
5 tracked IL-23 p19 drugs in the Psoriatic Arthritis race. The class explanation lives on the IL-23 p19 page; the full indication pipeline across every mechanism is on the Psoriatic Arthritis page.
4 approved / phase 41 Phase 3
Head-to-head evidence: guselkumab vs tildrakizumab · risankizumab vs tildrakizumab · tildrakizumab vs ustekinumab-stba (Steqeyma) · tildrakizumab vs ustekinumab-ttwe (Pyzchiva)